Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Cannabis Extract for Improving Quality of Life in Patients with Alzheimer's, Parkinson's, or ALS Using Dronabinol and Cannabidiol

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for people with neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD), and Parkinson's Disease (PD). The treatment being tested is a balanced extract of THC and CBD, known as the Cannabis Extract Avextra 10/10 Solution. The purpose of the study is to determine if this cannabis extract can safely and effectively improve the quality of life for patients with these conditions.

Participants in the study will receive either the cannabis extract or a placebo. The study will be conducted over a period of time, during which participants will take the treatment as an oral solution. The study aims to assess the safety and tolerability of the cannabis extract, as well as its impact on the quality of life, which will be measured using a health survey. Additionally, the study will look at how the treatment affects caregiver distress and patient-reported outcomes.

The study will also explore specific improvements in each disease group. For Alzheimer's Disease, it will assess cognitive functions and agitation. For Amyotrophic Lateral Sclerosis, it will evaluate functional status. For Parkinson's Disease, it will monitor the progression of symptoms. The results will help determine if the cannabis extract is a beneficial treatment option for these neurodegenerative diseases.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria related to age, diagnosis, and current treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, or Amyotrophic Lateral Sclerosis.

    Written informed consent is required, either personally or through a legally authorized representative.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish baseline health status. This includes evaluations using various scales and surveys to measure quality of life, cognitive functions, and disease-specific symptoms.

  3. Step 3

    Treatment phase

    Participants receive either the cannabis extract Avextra 10/10 oral solution or a placebo. The solution contains a balanced mixture of THC and CBD.

    The medication is administered orally, with the dosage and frequency determined by the study protocol. The duration of this phase is specified in the study timeline.

  4. Step 4

    Ongoing monitoring

    Regular monitoring is conducted to assess the safety and tolerability of the treatment. This includes tracking any adverse events and evaluating the impact on quality of life.

    Participants may be required to complete surveys and undergo medical evaluations at scheduled intervals.

  5. Step 5

    Final assessment

    At the end of the treatment phase, a final assessment is conducted to evaluate the overall impact of the treatment on quality of life and disease symptoms.

    The results are compared to the initial assessment to determine any improvements or changes.

  6. Step 6

    Study conclusion

    The study concludes with a review of all collected data to assess the effectiveness and safety of the treatment.

    Participants are informed of the study's findings and any potential next steps in their care.

Who can join the trial?

14 criteria

  • Patients must be able to give written permission to participate, either by themselves or through a legal representative.
  • Patients must be older than 55 years.
  • For patients with Alzheimer's Disease (AD):
    • Must have been diagnosed with AD based on specific criteria for major memory and thinking problems.
    • Must have a score of 24 or less on a test called MMSE, which checks memory and thinking skills.
    • Must show significant restlessness or agitation.
    • If taking medications to help with memory, the dose must not have changed for at least 3 months. If these medications were stopped, they can join after one month.
    • For patients with Amyotrophic Lateral Sclerosis (ALS):
      • Must have a confirmed or likely diagnosis according to specific criteria.
      • Must show disease progression in the last three months, measured by a decrease of at least one point on a specific scale.
      • Must have a lung function test result of 60% or more of what is expected.
      • Must have been taking a medication called riluzole at a dose of 50 mg twice a day for at least one month before the study starts.
      • For patients with Parkinson's Disease (PD):
        • Must have a diagnosis of Parkinson's disease with no known cause.
        • Must be in stages 1 to 4 of the disease, according to a specific scale.
        • Must be able to walk more than 10 meters without help.
        • Must be taking a medication called L-Dopa with a stable dose for at least 30 days.

Who cannot join the trial?

3 criteria

  • Patients who do not have a **neurodegenerative disease**. These are diseases that affect the brain and nerves, such as **Amyotrophic Lateral Sclerosis (ALS)**, **Alzheimer's Disease (AD)**, and **Parkinson's Disease (PD)**.
  • Patients who are not within the specified age range for the study.
  • Patients who belong to a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Avextra 10/10: This is a balanced cannabis extract containing equal parts of THC (tetrahydrocannabinol) and CBD (cannabidiol). It is used in this clinical trial to determine if it can improve the quality of life for patients with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). The trial aims to assess whether this extract is safe and effective in enhancing the overall well-being of patients by comparing it to a placebo.

What is already known about the treatment

Cannabis Extract Avextra 10/10 – This medication is administered as an oral solution and is currently being studied in a phase II clinical trial for its potential benefits in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD), and Parkinson's Disease (PD). The main therapeutic indication is to improve the quality of life for patients with these conditions. The mechanism of action involves a balanced extract of THC and CBD, which may interact with the endocannabinoid system to provide neuroprotective effects and alleviate symptoms. It is classified pharmacologically as a cannabinoid.

Investigated diseases

  • Amyotrophic Lateral Sclerosis (ALS)

    ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. It leads to the gradual degeneration and death of motor neurons, which are responsible for controlling voluntary muscles. As these neurons die, the brain loses the ability to initiate and control muscle movement, leading to muscle weakness and atrophy. Over time, individuals with ALS may experience difficulty speaking, swallowing, and breathing. The progression of symptoms varies among individuals, but it generally leads to increasing disability.

  • Alzheimer's Disease (AD)

    Alzheimer's Disease is a progressive neurological disorder that causes brain cells to degenerate and die, leading to a continuous decline in thinking, behavioral, and social skills. It is characterized by memory loss, confusion, and changes in behavior and personality. As the disease progresses, individuals may have difficulty recognizing family and friends, experience disorientation, and have trouble with language and reasoning. The progression of Alzheimer's Disease can vary, but it typically leads to severe cognitive impairment and loss of independence.

  • Parkinson's Disease (PD)

    Parkinson's Disease is a progressive nervous system disorder that affects movement. It develops gradually, often starting with a barely noticeable tremor in one hand. The disease is characterized by tremors, stiffness, and slowing of movement. As it progresses, individuals may experience difficulty with balance, coordination, and speech. The symptoms of Parkinson's Disease worsen over time, affecting daily activities and quality of life.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507715-35-02Protocol codeNEUROBISEstimated enrolment186 patientsSponsorAzienda Ospedaliero-Universitaria Maggiore Della Carita

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).